| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| WAYFIND-R | 21-30 | With a solid tumour and whose tumour has been profiled with a next-generation sequencing (NGS) test. |
WAYFIND-R aims to enable collaborations and to provide meaningful insights and high-quality evidence to enhance our understanding of precision oncology and ultimately transform the lives of people with cancer. |
DSSG Group: Basket (multiple types)
SABR COMET 3
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| SABR COMET 3 | CTRIAL-IE 19-21 | Oligometastatic disease who have one controlled primary solid tumour and 1-3 current metastatic lesions, and a maximum of 8 lifetime metastatic lesions |
The purpose of the study is to assess the impact of Stereotactic Ablative Radiotherapy (SABR), compared to standard of care (SOC) treatment, on overall survival, oncologic outcomes, and quality of life in patients with 1-3 current metastatic lesions. |
MK7339-002 / LYNK-002
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| MK7339-002 / LYNK-002 | CTRIAL-IE 19-27 | Multiple types of cancer |
This study will evaluate the efficacy and safety of olaparib monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic). |